Navigation Links
Cystic Fibrosis Foundation Lauds Congress for Passage of Small Business Innovation Research Program
Date:4/24/2008

Revised Law Includes Designated Funding for Rare Diseases

BETHESDA, Md., April 24 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation today lauded the U.S. House of Representatives for passing legislation to reauthorize the Small Business Innovation Research (SBIR) program.

In response to testimony from Robert J. Beall, Ph.D., president and CEO of the Foundation, the legislation includes a provision requiring that special attention be given to research for rare diseases, such as cystic fibrosis, when SBIR grants are awarded.

The SBIR program provides grants to small biotechnology and pharmaceutical companies for research and development programs focused on innovative treatments for rare diseases.

"We congratulate members of the House for recognizing the importance of funding for rare disease research and how critical these dollars are for cystic fibrosis and other devastating illnesses," said Beall. "The SBIR grants have been an important catalyst for several of our biotech collaborators working to find a cure. This special focus for the program is a win-win for everyone."

The Cystic Fibrosis Foundation was one of 20 organizations that supported the inclusion of rare disease research as an area of research that is "deserving of special attention in the SBIR program's reauthorization legislation." House Small Business Committee Chairwoman Nydia Velazquez (D-NY) and Ranking Republican Steve Chabot (R-OH) played a key role in the inclusion of this rare disease focus.

The legislation now moves to the U.S. Senate for consideration.

About the Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation is the leading organization in the United States devoted to curing and controlling cystic fibrosis. Headquartered in Bethesda, Md., the Foundation has more than 80 chapters and branch offices throughout the country and supports and accredits a nationwide network of more than 115 care centers. To advance the search for a cure, the Foundation has invested nearly $300 million in promising drug research in the biotech industry since 1998. For more information, visit http://www.cff.org.


'/>"/>
SOURCE Cystic Fibrosis Foundation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ibuprofen can slow lung disease in children with cystic fibrosis, Canadian study shows
2. Anaheim to Host Worlds Largest Cystic Fibrosis Medical Meeting
3. AMRI and Cystic Fibrosis Foundation Launch Major Research Collaboration
4. Cystic Fibrosis Foundation Named Charitable Organization of the Year by USA Track & Field
5. Cystic Fibrosis foundation lays out new treatment guidelines
6. Experts Release New Cystic Fibrosis Guidelines
7. Lung Transplants May Not Help Most Cystic Fibrosis Children
8. Ibuprofen associated with slower lung function decline in children with cystic fibrosis
9. Ibuprofen Preserves Lung Function in Kids With Cystic Fibrosis
10. Montana Passes Newborn Screening Law for Cystic Fibrosis
11. Cystic Fibrosis Foundation reports upward trend for key health outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
(Date:6/24/2016)... ... ... recruitment firm Slone Partners is pleased to announce the placement of Suzanne ... of North American Capital Sales at HTG Molecular . , In ... commercialization of the HTG EdgeSeq system and associated reagents in North America. , Headquartered ...
(Date:6/24/2016)... ... 24, 2016 , ... Today, MTI-GlobalStem, a provider of optimized ... difficult to transfect cells, announces its launch of the PluriQ™ G9™ Gene Editing ... is a complete system for culturing and transfecting human pluripotent stem cells ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016  Guerbet announced today that it has been ... Award . One of 12 suppliers to ... its support of Premier members through exceptional local customer ... commitment to lower costs. ... our outstanding customer service from Premier," says Massimo ...
(Date:6/23/2016)... , June 23, 2016  Experian ... integrating and transforming the patient payment and ... several innovative new products and services that ... its revenue cycle offerings. These award-winning solutions ... efficient workflows, remain compliant in an ever-changing ...
(Date:6/23/2016)... , June 23, 2016 Leading BioSciences ... address medical conditions resulting from a breakdown of ... appointed Greg Doyle as chief executive ... BioSciences, executive management team and board of directors, ... financial officer. He will provide continued leadership and ...
Breaking Medicine Technology: